levodopa has been researched along with pramipexole in 191 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (6.81) | 18.2507 |
| 2000's | 85 (44.50) | 29.6817 |
| 2010's | 76 (39.79) | 24.3611 |
| 2020's | 17 (8.90) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Kołodziejczyk, K; Maj, J; Rogóz, Z; Skuza, G | 1 |
| Carvey, PM; Ling, ZD; Pieri, S | 1 |
| Fernandez, HH; Friedman, JH | 1 |
| Althaus, JS; Fici, GJ; VonVoigtlander, PF | 1 |
| Carvey, PM; Ling, ZD; Robie, HC; Tong, CW | 1 |
| Oertel, WH; Pinter, MM; Pogarell, O | 1 |
| Bennett, JP; Piercey, MF | 1 |
| Appel, SH; Jankovic, J; Le, W; Rowe, DB; Xie, W; Zou, L | 1 |
| Galiano, ML; Grandas, F | 1 |
| Arnold, G; Kupsch, A | 1 |
| Phillips, P | 1 |
| Weiner, WJ | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| LeWitt, PA | 1 |
| Clarke C, E; Clarke J, A; Speller J, M | 2 |
| Anderson, WM; Gauger, L; Hauser, RA; Zesiewicz, TA | 1 |
| Cassel, W; Krüger, HP; Möller, JC; Oertel, WH; Peter, JH; Stiasny, K | 1 |
| Tanner, CM | 1 |
| Hebenstreit, E; Pinter, MM; Rutgers, AW | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Agapito, C; Bhattacharya, KF; Chaudhuri, KR; Pal, S | 1 |
| Guttman, M; Houle, S; Hussey, D; Kish, S; Stewart, D; Wilson, A | 1 |
| Ball, J | 1 |
| Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, S; Moramarco, A; Palagano, G; Zenzola, A | 1 |
| Etminan, M; Rochon, PA; Samii, A; Takkouche, B | 1 |
| Adler, CH; Blasucci, L; Carvey, P; Caviness, JN; Chase, WM; Ferry, JJ; Goetz, CG; Kompoliti, K; Leibowitz, MT; Leurgans, S; Pincus, JH; Raman, R; Tan, E; Yones, LC | 1 |
| Montgomery, EB | 2 |
| Jennings, D; Marek, K; Seibyl, J | 1 |
| Clarke, CE; Guttman, M | 1 |
| Quattrone, A; Zappia, M | 1 |
| Reichmann, H | 1 |
| Berardelli, A; De Pandis, MF; Modugno, N; Ruggieri, S; Stocchi, F; Thomas, A; Vacca, L; Valente, M | 1 |
| Bassi, A; Boffa, L; Brusa, L; Caramia, MD; Peppe, A; Pierantozzi, M; Ruggieri, S; Stanzione, P; Stefani, A | 1 |
| MacMahon, DG | 1 |
| Blackman, JA; Buck, ML; Conaway, MR; Patrick, PD | 1 |
| Morrish, PK | 1 |
| Bares, M; Dostál, V; Ehler, E; Fanfrdlová, Z; Fiedler, J; Klajblová, H; Kulist'ák, P; Rektor, I; Rektorová, I; Ressner, P; Svátová, J; Urbánek, K; Velísková, J | 1 |
| Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR | 1 |
| Inzelberg, R; Nisipeanu, P; Schechtman, E | 1 |
| Barone, P | 2 |
| Lu, CS; Mok, V; Shan, DE; Tsoi, TH; Wong, KS; Yang, CC | 1 |
| Krahn, M; Lang, A; Marras, C; Naglie, G; Tomlinson, G | 1 |
| Jankovic, J; Le, W; Pan, T | 1 |
| Kohno, Y; Takeuchi, S | 1 |
| Oertel, WH; Stiasny-Kolster, K | 1 |
| Alexander-Brown, B; Atassi, F; Barclay, L; Bennett, S; Berry, D; Biglan, K; Borchert, L; Brocht, A; Brown, D; Daigneault, S; DeAngelis, M; Dillon, S; Dobson, J; Evans, S; Factor, S; Fahn, S; Fontaine, D; Ford, B; Fussell, B; Hall, J; Hammerstad, J; Harrigan, M; Hodgeman, K; Holloway, RG; Hubble, J; Jankovic, J; Kamp, C; Kieburtz, K; Kurlan, R; Lang, A; LeWitt, P; Marek, K; McDermott, M; Miyasaki, J; Montgomery, A; Musch, B; O'Connell, C; Pahwa, R; Panisset, M; Pantella, C; Petsinger, G; Pfeiffer, B; Pfeiffer, R; Rainey, P; Rajput, A; Richard, K; Riley, D; Rodnitzky, R; Ross, T; Rost-Ruffner, E; Russell, DS; Seibyl, J; Shinaman, A; Shirley, T; Shoulson, I; Shults, C; Sime, E; Stacy, M; Standaert, D; Suchowersky, O; Sutherland, L; Tennis, M; Waters, C; Watts, A; Weeks, C; Weiner, W; Welsh, M; Wood, S; Wooten, F | 1 |
| Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
| Cassel, W; Haja, D; Körner, Y; Krüger, HP; Meindorfner, C; Möller, JC; Oertel, WH; Stiasny-Kolster, K | 1 |
| Bara-Jimenez, W; Chase, TN; Dimitrova, T; Favit, A; Mouradian, MM; Sherzai, A | 1 |
| Kurlan, R | 1 |
| Althoff, R; Jacobson, J; Martineau, RJ; Singh, A | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Bernauer, E; Finsterer, J | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Ogawa, N; Shimizu, M; Tanaka, K | 1 |
| Ahlskog, JE; Bower, JH; Josephs, KA; Klos, KJ; Matsumoto, JY | 1 |
| Schapira, AH | 1 |
| Dick, AW; Holloway, RG; Noyes, K | 1 |
| Brown, LA; Doan, J; Pellis, SM; Suchowersky, O; Whishaw, IQ | 1 |
| Bharmal, A; Lu, C; Suchowersky, O | 1 |
| Molnar, MZ; Mucsi, I; Novak, M | 1 |
| Klepac, N; Relja, M | 1 |
| Chigir', IP; Fedorova, NV | 1 |
| Chu, WB; Iravani, MM; Jackson, MJ; Jenner, P; Tayarani-Binazir, K | 1 |
| Kanzato, N; Murao, H; Nishihira, T; Takara, H | 1 |
| Hauser, RA; McDermott, MP; Messing, S | 1 |
| de Freitas, GR; Fontenelle, LF; Garcia, RF; Mendlowicz, MV; Nazar, BP; Ordacgi, L; Rosso, AL | 1 |
| Alonso-Navarro, H; Jiménez-Jiménez, FJ | 1 |
| Constantinescu, R; Kamp, C; Kieburtz, K; McDermott, MP; Romer, M | 1 |
| Biglan, KM; Holloway, RG; McDermott, MP; Richard, IH | 1 |
| Allen, RP; Hening, W; Tenzer, P; Winkelman, JW | 1 |
| Gigli, GL; Merlino, G; Robiony, F; Serafini, A; Valente, M | 1 |
| Dupuis, M; Evrard, F; Jacquerye, P; Muller, T | 1 |
| Auff, E; Kasprian, G; Leutmezer, F; Prayer, D; Seidel, S | 1 |
| Ball, E; Caivano, CK | 1 |
| Madigan, EJ | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| Bares, M; Krajcovicová, L; Rektor, I; Rektorová, I | 1 |
| Carrasco, E; Iranzo, A; Kumru, H; Marti, MJ; Santamaria, J; Tolosa, E; Valldeoriola, F | 1 |
| Bayliss, M; Harper, A; Nisbet, A; Saha, R; Scutt, A | 1 |
| Fukuyama, H; Hashikawa, K; Hattori, N; Kohriyama, T; Matsumoto, M; Ohshita, T; Takahashi, T; Yamashita, H | 1 |
| Arai, H; Hatta, K; Hattori, N; Ishikawa, K; Kamigaichi, R; Kubo, S; Mochizuki, H; Ogaki, K; Usui, C; Yokoyama, K | 1 |
| Audebert, C; Blin, O; Eusebio, A; Jouve, E; Micallef, J; Rey, M; Rouby, F; Tardieu, S | 1 |
| Kulisevsky, J; Martinez-Corral, M; Pagonabarraga, J | 1 |
| Ferini-Strambi, L | 1 |
| Cannas, A; Floris, G; Marrosu, F; Marrosu, MG; Piga, M; Serra, A; Solla, P; Tacconi, P | 1 |
| Ahlskog, JE; Bostwick, JM; Bower, JH; Hecksel, KA; Stevens, SR | 1 |
| Grimm, C; Kirch, W; Köberlein, J; Nelles, S; Pittrow, D; Rychlik, R | 1 |
| Bloem, BR; Gerschlager, W | 1 |
| Cho, JY; Cho, YJ; Hong, KS; Jeon, BS; Kim, HJ; Lee, DH; Park, SY; Seo, SY | 1 |
| Concolino, D; Mussa, A; Ponzone, A; Porta, F; Spada, M | 2 |
| Ballanger, B; Lang, AE; Miyasaki, JM; Pellecchia, G; Strafella, AP; van Eimeren, T | 1 |
| Ahn, YH; Lee, PH; Park, HJ; Shin, JY | 1 |
| Brodsky, MA; Nutt, JG; Park, BS | 1 |
| Jackson, MJ; Jenner, P; Olanow, CW; Rose, S; Tayarani-Binazir, KA | 1 |
| Marti, M; Morari, M; Viaro, R | 1 |
| Bergmann, L; Jost, WH | 1 |
| Artemova, IIu; Boĭko, AN; Ganzhula, PA; Ismailov, AM; Ivanov, AK; Khozova, AA; Levin, OS; Lisenker, LN; Nesterova, OS; Otcheskaia, OV; Rotor, LD; Vdovichenko, TV; Zhuravleva, EIu | 1 |
| Koester, J; Lang, AE; Potenza, MN; Siderowf, AD; Stacy, M; Voon, V; Weintraub, D; Whetteckey, J; Wunderlich, GR | 1 |
| Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N | 1 |
| Barone, P; Haaksma, M; Hauser, RA; Juhel, N; Mizuno, Y; Poewe, W; Rascol, O; Salin, L; Schapira, AH | 1 |
| de la Fuente-Fernández, R; Dinelle, K; Doudet, DJ; Mak, E; Schulzer, M; Sossi, V | 1 |
| Kitamura, Y | 1 |
| Rascol, O | 1 |
| Arami, MA; Ayromlou, H; Najmi, S | 1 |
| Arai, M | 1 |
| Hornyak, M; Kohnen, R; Kriston, L; Riemann, D; Scholz, H; Trenkwalder, C | 1 |
| Allen, RP; Ball, E; Calloway, MO; Higbie, RL; Lee, MR; Manjunath, R; Nisbet, PA; Ondo, WG | 1 |
| Adam, JJ; Duits, A; Scholtissen, B; van Houdt, H; Visser-Vandewalle, V; Winogrodzka, A | 1 |
| Antonini, A; Calandrella, D | 1 |
| Buttarelli, FR; Campanelli, D; Fanciulli, A; Misasi, R; Pontieri, FR | 1 |
| Bassetti, CL; Bornatico, F; Fuhr, P; Kallweit, U; Mathis, J; Schwander, J | 1 |
| Brioschi, A; Mauro, A; Pignatti, R; Semenza, C; Wenter, J; Zamarian, L | 1 |
| Coon, EA; Laughlin, RS | 1 |
| Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P | 1 |
| Nishijima, K; Saito, S; Shioda, K | 1 |
| Munhoz, RP; Teive, HA; Zavala, JA | 1 |
| de Biase, S; Gigli, GL; Lorenzut, S; Merlino, G; Valente, M | 1 |
| Barone, P; Busse, M; Debieuvre, C; Fraessdorf, M; Hauser, RA; Mizuno, Y; Poewe, W; Rascol, O; Schapira, AH | 1 |
| Aurora, RN; Bista, SR; Casey, KR; Kristo, DA; Lamm, CI; Rosenberg, RS; Rowley, JA; Tracy, SL; Zak, RS | 1 |
| Daghem, M; Grosset, DG; Grosset, KA; Macphee, GJ; Newman, EJ; Nissen, T; Odin, P; Pal, G; Stewart, M | 1 |
| Abdolahi, A; Biglan, KM; Dorsey, ER; Killoran, A; Scoglio, N | 1 |
| Bagetta, V; Calabresi, P; Del Papa, G; Gardoni, F; Ghiglieri, V; Giampà, C; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A; Zianni, E | 1 |
| Chen, JF; Eberly, S; Kamp, C; Lang, AE; McDermott, MP; Messing, S; Oakes, D; Schwarzschild, MA; Tanner, CM; Tennis, M; Togasaki, D; Wills, AM | 1 |
| Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H | 1 |
| Jenner, P | 1 |
| Sheehan, J; Thorpe, M; Wilson, L | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Béhé, M; Depboylu, C; Hermanns, G; Höglinger, GU; Matusch, A; Maurer, L; Oertel, WH; Windolph, A | 1 |
| Bachmann, CG; Berg, D; Berkels, R; Grieger, F; Hofmann, WE; Lauterbach, T; Schollmayer, E; Stiasny-Kolster, K | 1 |
| Borroni, B; Cotelli, MS; Filosto, M; Marchina, E; Padovani, A; Premi, E | 1 |
| Ishii, K; Katayama, Y; Nagayama, H; Nakajima, N; Nishiyama, Y; Ueda, M | 1 |
| Snider, S | 1 |
| Bonastre, M; Cortés, R; Giralt, A; Marin, C; Mengod, G; Obeso, JA; Schapira, AH | 1 |
| Alonso-Canovas, A; Garcia-Ruiz, PJ; Herranz Barcenas, A; Mahillo Fernandez, I; Martinez Castrillo, JC; Mata, M; Olmedilla Gonzalez, N; Sanchez Alonso, P; Vela, L | 1 |
| Bassetti, CL; Ferini-Strambi, L; Fulda, S; Maestri, M; Manconi, M; Marelli, S; Staedler, C; Zucconi, M | 1 |
| Hattori, N | 1 |
| Frampton, JE | 1 |
| Enomoto, H; Hanajima, R; Kadowaki, S; Kobayashi, S; Moriya, A; Nakamura, K; Nakatani-Enomoto, S; Terao, Y; Ugawa, Y; Yoshihara, A | 1 |
| Doyu, M; Ibi, T; Niwa, J; Taguchi, S | 1 |
| Chiu, WH; Depboylu, C; Hermanns, G; Höglinger, GU; Maurer, L; Oertel, WH; Ries, V; Windolph, A | 1 |
| Bauer, L; Chung, SJ; Ikeda, J; Jeon, BS; Kim, JM; Kim, JW; Singh, P; Thierfelder, S | 2 |
| Fernández-Bobadilla, R; Gironell, A; Kulisevsky, J; Martínez-Horta, S; Pagonabarraga, J; Pascual-Sedano, B; Pérez-Pérez, J; Sierra, S | 1 |
| Fernández, E; Fresno, C; Gershanik, OS; Gomez, G; González, GA; Larramendy, C; Murer, MG; Saborido, MD; Spaans, F; Taravini, IR | 1 |
| Cao, ZH; Chen, HX; Ding, ZG; Song, JH; Zhang, GB; Zhou, PY | 1 |
| Chen, H; Guo, Y; Hao, H; Jia, F; Li, L; Wan, S; Zhang, J | 1 |
| Titova, NV | 1 |
| Jeon, BS; Park, H; Park, SH; Shin, JH | 1 |
| Cicero, CE; Mostile, G; Nicoletti, A; Zappia, M | 1 |
| da Costa, AN; Dardou, D; Dremier, S; Durif, F; Hafidi, A; Hanon, E; Loiodice, S; Ouachikh, O; Winlow, P | 1 |
| Jo, J; Mousa, SA; Sahli, ZT; Tarazi, FI | 1 |
| Assis, F; Barbosa, IG; Christo, PP; de Souza, MS; Reis, HJ; Rocha, NP; Scalzo, PL; Teixeira, AL; Vieira, ÉLM | 1 |
| Park, D | 1 |
| Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C | 1 |
| Clemm von Hohenberg, C; Dreßing, H | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Argyelan, M; DeLucia, I; Eidelberg, D; Fitzpatrick, T; Gluck, M; Herzallah, M; Moustafa, AA; Sako, W; Sarpal, D; Vo, A | 1 |
| Hudson A, L; Miranda C, M | 1 |
| Aiyappan, V; Tashkent, Y | 1 |
| Elshahed, MS; Hegazy, MA; Helmy, MI; Mohamed, D; Toubar, SS | 1 |
| Doladé, NG; Figueras, A; García, GC; Lanteri, PF; Leguia, A | 1 |
| Acıbuca, A; Akbostancı, C; Efe, TH; Erken Pamukcu, H; Gerede Uludağ, DM; Sorgun, MH; Tekin Tak, B; Turhan, S | 1 |
| Baik, JS; Cho, J; Jeon, B; Kim, HT; Kim, JM; Kim, JW; Koh, SB; Kwon, OD; Lee, HW; Lee, JY; Ma, HI; Yoon, WT | 1 |
| Capuano, A; Rafaniello, C; Rossi, F; Scavone, C; Sportiello, L; Stelitano, B | 1 |
| Cooper, J; Ni, X; Ning, Y; Parks, D; Refoios Camejo, R; Yi, B; Zhao, H | 1 |
| Aktürk, T; Güntekin, B; Hanoğlu, L; Hanoğlu, T; Yulug, B | 1 |
| Adalid-Peralta, L; Álvarez-Luquin, D; Ángeles-Perea, S; Arce-Sillas, A; Boll, MC; Espinosa-Cárdenas, R; Fragoso, G; Garcia-Garcia, E; González-Saavedra, I; Leyva-Hernández, J; Montes-Moratilla, E; Sciutto, E | 1 |
| Ding, J; Hong, W; Huang, J; Ren, Y; Yang, Z | 1 |
| Bonastre, M; Fuentes, M; Marin, C; Mullol, J | 1 |
| Frucht, S; Han, SC; Katus, L | 1 |
| Abbasi, MH; Esmaeili, S; Habibi, SA; Shahidi, GA | 1 |
| Costa, G; Marongiu, J; Morelli, M; Serra, M; Simola, N | 1 |
| Jiang, DQ; Jiang, LL; Li, MX; Qiao, JY; Wang, Y; Zang, QM | 1 |
| Ando, H; Doyu, M; Fujikake, A; Fukuoka, T; Hayashi, M; Ito, C; Izumi, M; Kawagashira, Y; Koide, H; Nakashima, K; Niwa, JI; Ogawa, K; Oiwa, H; Okada, Y; Taguchi, S; Tokui, K; Tsunoda, Y; Yasumoto, A; Yuasa, T | 1 |
| Jiang, DQ; Jiang, LL; Li, MX; Lu, CS; Wang, Y | 1 |
| Avegno, EM; Barattini, AE; Callicoatte, CN; Cucinello-Ragland, JA; Edwards, KN; Edwards, S; Gilpin, NW; Melain, A; Pahng, AR | 1 |
| Brotchie, J; Friedman, H; Giladi, N; Hauser, RA; Litman, P; Oren, S; Poewe, W | 1 |
| Chen, FF; Chen, XT; Wen, SY; Zhang, Q; Zhou, CQ | 1 |
| Neirotti, A; Porta, F; Spada, M | 1 |
| Artusi, CA; Bozzali, M; Covolo, A; Imbalzano, G; Ledda, C; Lopiano, L; Martone, T; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Chen, F; Chen, X; Wen, S; Zhang, Q; Zhou, C | 1 |
| Belloso-Iguerategui, A; Cotman, CW; Fernández-Irigoyen, J; Gago, B; Merino-Galan, L; Prieto, GA; Quiroga-Varela, A; Rodríguez-Chinchilla, T; Rodríguez-Oroz, MC; Santamaria, E; Zamarbide, M | 1 |
45 review(s) available for levodopa and pramipexole
| Article | Year |
|---|---|
Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Humans; Levodopa; Motor Activity; Parkinson Disease; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles | 1999 |
[Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease].
Topics: Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 1999 |
The initial treatment of Parkinson's disease should begin with levodopa.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Drug Therapy, Combination; Essential Tremor; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine; Thiazoles; Time Factors | 1999 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
New drugs for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Synergism; Enzyme Inhibitors; Ergolines; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 2000 |
Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Tolerance; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles | 2000 |
Pramipexole for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine Agonists; Humans; Levodopa; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles | 2000 |
["Sleep attacks" in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists?].
Topics: Accidents, Traffic; Automobile Driving; Benzothiazoles; Contraindications; Dopamine Agents; Dopamine Agonists; Germany; Humans; Indoles; Legislation, Drug; Levodopa; Narcolepsy; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Topics: Antiparkinson Agents; Benzothiazoles; Disorders of Excessive Somnolence; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; MEDLINE; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles | 2001 |
Two advances in the management of Parkinson disease.
Topics: Age Factors; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dyskinesias; Electric Stimulation Therapy; Forecasting; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Stereotaxic Techniques; Thiazoles | 2002 |
DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease.
Topics: Benzothiazoles; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Psychomotor Disorders; Randomized Controlled Trials as Topic; Thiazoles | 2002 |
Do dopamine agonists or levodopa modify Parkinson's disease progression?
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Carrier Proteins; Dihydroxyphenylalanine; Disease Progression; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Humans; Indoles; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes | 2002 |
Dopamine agonist monotherapy in Parkinson's disease.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2002 |
Neuroprotection in idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Cell Death; Dopamine Agonists; Humans; Indoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2002 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Clinical strategies to prevent and delay motor complications.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
[Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole].
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles | 2004 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Present and future drug treatment for Parkinson's disease.
Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Indoles; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Psychomotor Performance; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Substantia Nigra; Thiazoles; Urinary Incontinence | 2005 |
Management of restless legs syndrome in patients on dialysis.
Topics: Amines; Anticonvulsants; Benzothiazoles; Clonazepam; Cyclohexanecarboxylic Acids; Dopamine Agents; Gabapentin; gamma-Aminobutyric Acid; Humans; Kidney Failure, Chronic; Levodopa; Narcotics; Pramipexole; Renal Dialysis; Restless Legs Syndrome; Thiazoles; Uremia | 2006 |
Restless legs syndrome: nonpharmacologic and pharmacologic treatments.
Topics: Amines; Anemia, Iron-Deficiency; Anticonvulsants; Benzothiazoles; Clonazepam; Cyclohexanecarboxylic Acids; Dopamine Agents; Dopamine Agonists; Ferritins; Gabapentin; gamma-Aminobutyric Acid; Humans; Indoles; Iron; Levodopa; Pramipexole; Restless Legs Syndrome; Trace Elements | 2007 |
Clinical experience with pramipexole in the treatment of restless legs syndrome.
Topics: Adult; Benzothiazoles; Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Pramipexole; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Severity of Illness Index | 2008 |
Internal medicine: guidance to the diagnosis and management of restless legs syndrome.
Topics: Benzothiazoles; Critical Pathways; Cross-Sectional Studies; Dopamine Agonists; Humans; Indoles; Internal Medicine; Levodopa; Polysomnography; Pramipexole; Primary Health Care; Restless Legs Syndrome; Risk Factors; Treatment Outcome | 2008 |
Treatment options for restless legs syndrome.
Topics: Benzothiazoles; Dopamine Agonists; Humans; Indoles; Levodopa; Pramipexole; Restless Legs Syndrome | 2009 |
[Clinical data of the prolonged-release formulation of ropinirole].
Topics: Antiparkinson Agents; Benzothiazoles; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Quality of Life | 2010 |
[Dopaminergic neuroprotection and reconstruction of neural network tiara].
Topics: Animals; Azepines; Benzothiazoles; Brain; Dopamine; Dopamine Agonists; Embryonic Stem Cells; Humans; Levodopa; Mice; Microglia; Nerve Net; Nerve Regeneration; Neuroprotective Agents; Parkinson Disease; Planarians; Pramipexole; Rats | 2010 |
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2011 |
Treatment of depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Depression; Desipramine; Dopamine Agonists; Humans; Levodopa; Nortriptyline; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2011 |
Dopamine agonists for restless legs syndrome.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Levodopa; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Severity of Illness Index | 2011 |
Pharmacokinetic evaluation of pramipexole.
Topics: Benzothiazoles; Dopamine Agonists; Drug Delivery Systems; Drug Evaluation; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Heart Valve Diseases; Humans; Levodopa; Parkinson Disease; Pharmacogenetics; Pramipexole; Receptors, Dopamine; Restless Legs Syndrome | 2011 |
ADMET considerations for restless leg syndrome drug treatments.
Topics: Amines; Anticonvulsants; Benzothiazoles; Carbamates; Cyclohexanecarboxylic Acids; Dopamine Agents; Dopamine Agonists; Ergolines; Gabapentin; gamma-Aminobutyric Acid; Humans; Indoles; Levodopa; Neuralgia; Pramipexole; Pregabalin; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2012 |
The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.
Topics: Academies and Institutes; Benzothiazoles; Cabergoline; Carbamates; Dopamine Agents; Ergolines; Evidence-Based Medicine; gamma-Aminobutyric Acid; Humans; Indoles; Levodopa; Nocturnal Myoclonus Syndrome; Pergolide; Peripheral Nervous System Diseases; Pramipexole; Restless Legs Syndrome; Sleep Medicine Specialty; United States; Venous Insufficiency | 2012 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
The impact of restless legs syndrome: a familial case study.
Topics: Adult; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Benzothiazoles; Carbidopa; Dopamine Agonists; Drug Combinations; Family Health; Humans; Incidence; Indoles; Levodopa; Male; Middle Aged; Pramipexole; Prevalence; Restless Legs Syndrome | 2013 |
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].
Topics: Benserazide; Benzothiazoles; Catechols; Circadian Rhythm; Dementia; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Dyskinesias; Education, Medical, Continuing; Hallucinations; Humans; Levodopa; Nitriles; Parkinson Disease; Practice Guidelines as Topic; Pramipexole; Reference Standards; Referral and Consultation | 2014 |
Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Topics: Activities of Daily Living; Administration, Oral; Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Motor Activity; Parkinson Disease; Patient Acuity; Pramipexole; Treatment Outcome | 2014 |
[A current view on dopamine receptor agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Controlled Clinical Trials as Topic; Dopamine Agonists; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Pramipexole; Quality of Life; Tremor | 2015 |
Clinical management of restless legs syndrome in end-stage renal disease patients.
Topics: Amines; Analgesics, Opioid; Benzodiazepines; Benzothiazoles; Comorbidity; Cyclohexanecarboxylic Acids; Dopamine Agonists; Excitatory Amino Acid Antagonists; Exercise Therapy; Gabapentin; gamma-Aminobutyric Acid; Humans; Indoles; Intermittent Pneumatic Compression Devices; Kidney Failure, Chronic; Levodopa; Massage; Pramipexole; Quality of Life; Renal Dialysis; Restless Legs Syndrome; Sleep Hygiene; Tetrahydronaphthalenes; Thiophenes | 2017 |
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes | 2017 |
Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Combined Modality Therapy; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2019 |
Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis.
Topics: Antiparkinson Agents; Combined Modality Therapy; Humans; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Pramipexole; Treatment Outcome | 2021 |
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.
Topics: Humans; Indans; Levodopa; Parkinson Disease; Pramipexole | 2022 |
Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta-analysis.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agonists; Humans; Levodopa; Network Meta-Analysis; Parkinson Disease; Pramipexole | 2023 |
Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.
Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Network Meta-Analysis; Parkinson Disease; Pergolide; Pramipexole | 2023 |
41 trial(s) available for levodopa and pramipexole
| Article | Year |
|---|---|
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles | 1999 |
[Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease].
Topics: Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 1999 |
Pramipexole-induced somnolence and episodes of daytime sleep.
Topics: Aged; Antiparkinson Agents; Automobile Driving; Benzothiazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Narcolepsy; Parkinson Disease; Polysomnography; Pramipexole; Retrospective Studies; Thiazoles | 2000 |
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Topics: Antiparkinson Agents; Benzothiazoles; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Dyskinesias; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Proportional Hazards Models; Quality of Life; Radiopharmaceuticals; Thiazoles; Tomography, Emission-Computed, Single-Photon | 2000 |
An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 2000 |
Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain Chemistry; Carbon Radioisotopes; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Receptors, Dopamine; Thiazoles; Tomography, Emission-Computed | 2001 |
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain; Cocaine; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Regression Analysis; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2002 |
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzothiazoles; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Parkinson Disease; Postmenopause; Pramipexole; Sex Factors; Thiazoles | 2002 |
Combination of two different dopamine agonists in the management of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 2002 |
Pramipexole in comparison to l-dopa: a neuropsychological study.
Topics: Aged; Analysis of Variance; Benzothiazoles; Cognition Disorders; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pergolide; Placebos; Pramipexole; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Single-Blind Method; Thiazoles; Treatment Outcome | 2003 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
Topics: Adult; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Female; Hong Kong; Humans; Levodopa; Male; Parkinson Disease; Pramipexole; Software Design; Taiwan; Thiazoles; Treatment Outcome | 2003 |
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Pramipexole; Quality of Life; Thiazoles | 2004 |
Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Benzothiazoles; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Levodopa; Male; Middle Aged; Polysomnography; Pramipexole; Restless Legs Syndrome; Severity of Illness Index; Sleep Wake Disorders; Thiazoles; Treatment Outcome | 2004 |
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Topics: Aged; Benzothiazoles; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Thiazoles | 2004 |
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pilot Projects; Pramipexole; Thiazoles | 2004 |
Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Benzothiazoles; Cost-Benefit Analysis; Double-Blind Method; Female; Health Expenditures; Humans; Levodopa; Male; Parkinson Disease; Pramipexole; Prospective Studies; Reproducibility of Results; Sex Factors; Thiazoles; Time Factors; Treatment Outcome | 2005 |
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Arm; Benzothiazoles; Biomechanical Phenomena; Carbidopa; Catechols; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 2006 |
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Prospective Studies; Retrospective Studies | 2006 |
Impact of pramipexole on the onset of levodopa-related dyskinesias.
Topics: Aged; Akathisia, Drug-Induced; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Probability | 2007 |
Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.
Topics: Adult; Age Distribution; Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Cohort Studies; Comorbidity; Disorders of Excessive Somnolence; Double-Blind Method; Edema; Female; Hallucinations; Heart Diseases; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pramipexole; Risk Factors; Sex Distribution | 2007 |
Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cross-Over Studies; Double-Blind Method; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Pramipexole; Sleep Wake Disorders; Treatment Outcome; Young Adult | 2009 |
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cohort Studies; Disability Evaluation; Disease Progression; Early Diagnosis; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Quality of Life; Time; Treatment Outcome | 2009 |
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
Topics: Benzothiazoles; Dopamine Agonists; Frontal Lobe; Gambling; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Pramipexole; Psychomotor Performance; Reward; Risk-Taking | 2009 |
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Brain; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Risk Assessment; Treatment Outcome | 2010 |
[Effect of dopamine agonist pramipexole (mirapex) on tremor, affective disorders and quality of life in patients with Parkinson's disease].
Topics: Adult; Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Pramipexole; Quality of Life; Tremor | 2010 |
Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Pramipexole; Quality of Life; Severity of Illness Index; Treatment Outcome | 2010 |
Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Female; Flow Cytometry; Gene Expression Regulation; Humans; Indoles; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Pramipexole | 2011 |
Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
Topics: Adult; Aged; Benserazide; Benzothiazoles; Cross-Over Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Pramipexole; Restless Legs Syndrome; Sleep; Treatment Outcome | 2011 |
Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Drug Substitution; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Caffeine consumption and risk of dyskinesia in CALM-PD.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Benzothiazoles; Caffeine; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Retrospective Studies; Risk | 2013 |
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2013 |
Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Germany; Humans; Levodopa; Male; Middle Aged; Pramipexole; Restless Legs Syndrome; Self Administration; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Delayed-Action Preparations; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Polysomnography; Pramipexole; Restless Legs Syndrome; Sleep Stages; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2014 |
Effects of L-Dopa and pramipexole on plasticity induced by QPS in human motor cortex.
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Double-Blind Method; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Long-Term Potentiation; Male; Middle Aged; Motor Cortex; Muscle, Skeletal; Pramipexole; Transcranial Magnetic Stimulation | 2015 |
Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Drug Substitution; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Tetrahydronaphthalenes; Thiophenes | 2015 |
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes | 2015 |
Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Benserazide; Benzothiazoles; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Periodicity; Piribedil; Postural Balance; Pramipexole; Walking | 2015 |
Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug Combinations; Drug Substitution; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2019 |
Efficacy of pramipexole combined with levodopa for Parkinson's disease treatment and their effects on QOL and serum TNF-
Topics: Antiparkinson Agents; Benzothiazoles; Humans; Levodopa; Parkinson Disease; Pramipexole; Quality of Life; Tumor Necrosis Factor-alpha | 2020 |
107 other study(ies) available for levodopa and pramipexole
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Topics: Animals; Antiparkinson Agents; Benzazepines; Benzothiazoles; Body Temperature; Catalepsy; Clozapine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Injections, Subcutaneous; Levodopa; Male; Mice; Motor Activity; Pramipexole; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Spiperone; Stereotyped Behavior; Sulpiride; Thiazoles | 1997 |
Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Cell Count; Cell Survival; Culture Media, Conditioned; Dopamine Agonists; Female; Immunohistochemistry; Levodopa; Mesencephalon; Neurons; Pramipexole; Rats; Rats, Sprague-Dawley; Stereoisomerism; Thiazoles; Tyrosine 3-Monooxygenase | 1997 |
New anti-parkinsonian drugs.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 1998 |
Pharmacological approaches to counter the toxicity of Dopa.
Topics: Animals; Benzothiazoles; Cells, Cultured; Cerebellum; Cytoplasmic Granules; Glutathione; Levodopa; Neuroprotective Agents; Pramipexole; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Selegiline; Thiazoles; Vitamin E | 1998 |
Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Topics: Animals; Antioxidants; Benzothiazoles; Cell Count; Cell Survival; Cells, Cultured; Culture Media, Conditioned; Dopamine Agents; Dopamine Agonists; Levodopa; Mesencephalon; Neuroprotective Agents; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles; Tyrosine 3-Monooxygenase; Vitamin E | 1999 |
Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity.
Topics: Animals; Benzothiazoles; Cell Line; Cell Survival; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Glioma; Hybrid Cells; Kinetics; Levodopa; Neuroblastoma; Neuroprotective Agents; Pramipexole; Thiazoles | 1999 |
[High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pramipexole; Thiazoles | 1999 |
Several classes of new drugs emerging for Parkinson disease.
Topics: Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Enzyme Inhibitors; Humans; Indoles; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 1999 |
Dopamine agonists in early therapy for Parkinson disease: promise and problems.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cabergoline; Disorders of Excessive Somnolence; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies; Thiazoles | 2001 |
Current advances in Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Benzothiazoles; Brain Stem; Catechols; Depression; Dopamine Agonists; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles | 2001 |
Efficacy and tolerability of dopamine agonists in a parkinsonian population.
Topics: Age of Onset; Aged; Aging; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Ergolines; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome | 2001 |
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
Topics: Antiparkinson Agents; Area Under Curve; Benzothiazoles; Biological Availability; Body Weight; Drug Interactions; Female; Humans; Levodopa; Male; Pramipexole; Sex Characteristics; Thiazoles | 2002 |
The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
Topics: Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Thiazoles | 2003 |
The use of dopamine enhancing medications with children in low response states following brain injury.
Topics: Adolescent; Adult; Amantadine; Arousal; Awareness; Benzothiazoles; Brain Injuries; Bromocriptine; Child; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Methylphenidate; Neuropsychological Tests; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome; Unconsciousness | 2003 |
REAL and CALM: what have we learned?
Topics: Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Corpus Striatum; Disease Progression; Dopamine; Feasibility Studies; Humans; Indoles; Levodopa; Neurons; Neuroprotective Agents; Parkinson Disease; Pramipexole; Putamen; Reference Values; Sensitivity and Specificity; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2003 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Slowing Parkinson's disease progression: recent dopamine agonist trials.
Topics: Antiparkinson Agents; Artifacts; Benzothiazoles; Clinical Trials as Topic; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Severity of Illness Index; Single-Blind Method; Thiazoles | 2004 |
Slowing Parkinson's disease progression: recent dopamine agonist trials.
Topics: Antiparkinson Agents; Benzothiazoles; Biological Transport; Cell Line, Tumor; Clinical Trials as Topic; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Humans; In Vitro Techniques; Indoles; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuroblastoma; Parkinson Disease; Pramipexole; Thiazoles | 2004 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
Predictors of sudden onset of sleep in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Comorbidity; Cross-Sectional Studies; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Narcolepsy; Parkinson Disease; Pramipexole; Risk Factors; Surveys and Questionnaires; Thiazoles | 2004 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome | 2005 |
Pramipexole, ropinirole, and mania in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Bipolar Disorder; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2005 |
Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.
Topics: Anti-Bacterial Agents; Antiparkinson Agents; Benzothiazoles; Brain; Chronic Disease; Dipeptides; Evoked Potentials, Visual; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Paromomycin; Pramipexole; Recovery of Function; Thiazoles; Treatment Outcome; Vision Disorders | 2005 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; Benzothiazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electron Spin Resonance Spectroscopy; Functional Laterality; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinson Disease; Pramipexole; Thiazoles; Time Factors | 2005 |
Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Catechols; Databases, Factual; Dopamine Agonists; Humans; Indoles; Levodopa; Male; Mental Disorders; Middle Aged; Multiple System Atrophy; Nitriles; Parkinson Disease; Pramipexole; Sexual Dysfunctions, Psychological; Thiazoles | 2005 |
Gambling and Parkinson disease.
Topics: Antiparkinson Agents; Benzothiazoles; Gambling; Humans; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Thiazoles | 2006 |
A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Case-Control Studies; Cognition; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pramipexole | 2006 |
[Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
Topics: Anxiety; Benzothiazoles; Carbidopa; Delayed-Action Preparations; Depression; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Receptors, Dopamine D1; Thiazoles; Treatment Outcome | 2006 |
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\\ increased motor disability.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzothiazoles; Callithrix; Data Interpretation, Statistical; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Piperazines; Pramipexole; Pyridines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists | 2006 |
[Case of juvenile parkinsonism in pregnancy].
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Contraindications; Dopamine Agents; Dopamine Agonists; Ergolines; Family Planning Services; Female; Humans; Infant, Newborn; Levodopa; Parkinsonian Disorders; Pramipexole; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiazoles | 2006 |
Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Parkinsonian Disorders; Pergolide; Pramipexole; Recurrence | 2007 |
Panic attack like episodes possibly associated with pramipexole therapy in Parkinson's disease.
Topics: Anxiety Disorders; Benzothiazoles; Carbidopa; Central Nervous System; Diazepam; Dopamine Agonists; Dose-Response Relationship, Drug; Female; GABA Agonists; Humans; Levodopa; Middle Aged; Panic Disorder; Parkinson Disease; Pramipexole; Self Administration | 2007 |
[Isolated pulmonary hypertension and pergolide].
Topics: Antiparkinson Agents; Benserazide; Benzothiazoles; Blood Pressure; Catechols; Dyspnea; Echocardiography; Humans; Hypertension, Pulmonary; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease, Postencephalitic; Pergolide; Pramipexole | 2008 |
Disruption of nigrostriatal and cerebellothalamic pathways in dopamine responsive Holmes' tremor.
Topics: Benzothiazoles; Cerebellum; Cerebral Hemorrhage; Diffusion Magnetic Resonance Imaging; Dopamine Agents; Female; Humans; Levodopa; Magnetic Resonance Imaging; Neostriatum; Neural Pathways; Pramipexole; Substantia Nigra; Syndrome; Thalamus; Tomography, Emission-Computed, Single-Photon; Tremor; Young Adult | 2009 |
A 77-year-old man with Parkinson's disease and hyperthermia.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Combined Modality Therapy; Emergency Service, Hospital; Emergency Treatment; Follow-Up Studies; Humans; Levodopa; Male; Malignant Hyperthermia; Neuroleptic Malignant Syndrome; Parkinson Disease; Pramipexole; Risk Assessment; Treatment Outcome | 2008 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Echocardiography; Female; Heart Valve Diseases; Heart Valves; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole | 2008 |
Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Arousal; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Polysomnography; Pramipexole; Prospective Studies; REM Sleep Behavior Disorder; Video Recording | 2008 |
Late onset dopa-responsive dystonia with tremor, gait freezing and behavioural disturbance and a normal dopamine transporter scan.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Diagnosis, Differential; Dopamine Agents; Drug Therapy, Combination; Dystonia; Female; Gait Disorders, Neurologic; Humans; Levodopa; Pramipexole; Tremor | 2008 |
[Case of a 30-year history of PARK6 --findings from functional imaging of the brain].
Topics: Antiparkinson Agents; Benzothiazoles; Diagnostic Imaging; Female; Humans; Levodopa; Middle Aged; Mutation, Missense; Parkinsonian Disorders; Pramipexole; Protein Kinases; Receptors, Dopamine D2; Time Factors | 2008 |
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
Topics: Aged; Antiparkinson Agents; Azepines; Benzothiazoles; Cabergoline; Carbidopa; Catatonia; Catechols; Drug Therapy, Combination; Electroconvulsive Therapy; Ergolines; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2009 |
Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity.
Topics: Antiparkinson Agents; Arm; Art; Benzothiazoles; Brain; Cabergoline; Creativity; Depressive Disorder; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Motor Skills; Obsessive Behavior; Paintings; Parkinson Disease; Pramipexole | 2009 |
Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Benzothiazoles; Brain; Carbidopa; Dopamine Agents; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Tomography, Emission-Computed, Single-Photon; Tropanes | 2009 |
Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Compulsive Behavior; Dopamine Agonists; Female; Gambling; Humans; Indoles; Levodopa; Libido; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies | 2009 |
[Socioeconomic relevance of the idiopathic restless legs syndrome (RLS) in Germany: cost-of-illness study].
Topics: Benzothiazoles; Delayed-Action Preparations; Dopamine Agents; Dopamine Agonists; Drug Costs; Financing, Personal; Germany; Health Care Costs; Humans; Indoles; Levodopa; Long-Term Care; Markov Chains; Models, Economic; National Health Programs; Practice Guidelines as Topic; Pramipexole; Resource Allocation; Restless Legs Syndrome; Socioeconomic Factors; Treatment Outcome | 2009 |
Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Drug Therapy, Combination; Follow-Up Studies; Gambling; Humans; Levodopa; Male; Parkinson Disease; Pramipexole | 2009 |
Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Comorbidity; Disability Evaluation; Dopamine Agonists; Female; Gastrointestinal Diseases; Humans; Indoles; Levodopa; Male; Memory Disorders; Middle Aged; Mood Disorders; Movement Disorders; Neurologic Examination; Nocturia; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Prevalence; Restless Legs Syndrome; Treatment Outcome | 2009 |
Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency.
Topics: Adult; Benzothiazoles; Child; Child, Preschool; Dopamine Agonists; Female; Follow-Up Studies; Humans; Levodopa; Male; Metabolic Diseases; Phosphorus-Oxygen Lyases; Pramipexole; Young Adult | 2009 |
Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Topics: Animals; Antiparkinson Agents; bcl-2-Associated X Protein; Benzothiazoles; Cell Count; Disease Models, Animal; Dopamine; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Glutathione; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Statistics, Nonparametric; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Callithrix; Carbidopa; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Motor Activity; MPTP Poisoning; Pramipexole; Time Factors | 2010 |
Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
Topics: Amisulpride; Animals; Antiparkinson Agents; Benzimidazoles; Benzothiazoles; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neural Inhibition; Nociceptin; Opioid Peptides; Parkinsonian Disorders; Piperidines; Pramipexole; Pyridines; Reaction Time; Receptors, Dopamine D3; Sulpiride | 2010 |
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Binge-Eating Disorder; Comorbidity; Cross-Sectional Studies; Disruptive, Impulse Control, and Conduct Disorders; Female; Gambling; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prevalence; Risk Factors; Sexual Dysfunctions, Psychological | 2010 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome | 2010 |
Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release.
Topics: Animals; Benzothiazoles; Biomarkers; Brain; Dopamine; Dopamine Agonists; Levodopa; Male; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Presynaptic Terminals; Rats; Rats, Sprague-Dawley | 2010 |
Hemiparkinsonism-hemiatrophy syndrome.
Topics: Adult; Antiparkinson Agents; Atrophy; Benzothiazoles; Biperiden; Carbidopa; Cerebral Cortex; Cerebral Ventricles; Dopamine Agonists; Drug Combinations; Humans; Indans; Levodopa; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Pramipexole; Tomography, X-Ray Computed | 2011 |
Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.
Topics: Aged; Arginine Vasopressin; Benzothiazoles; Carbidopa; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole | 2011 |
Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.
Topics: Adult; Aged; Benzothiazoles; Cross-Sectional Studies; Dopamine Agonists; Female; Health Surveys; Humans; Indoles; Levodopa; Male; Middle Aged; Outpatients; Patient Satisfaction; Pergolide; Pramipexole; Restless Legs Syndrome; Risk Factors; Treatment Failure | 2011 |
Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance.
Topics: Aged; Benserazide; Benzothiazoles; Carbidopa; Cues; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Psychomotor Performance; Reaction Time; Subthalamic Nucleus | 2011 |
Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy?
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Compulsive Behavior; Decision Making; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Gambling; Humans; Levodopa; Matched-Pair Analysis; Neuropsychological Tests; Parkinsonian Disorders; Pramipexole; Reference Values | 2012 |
Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Burning Mouth Syndrome; Carbidopa; Dopamine; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Pramipexole | 2012 |
Dopamine agonists in dihydropteridine reductase deficiency.
Topics: Adult; Behavior; Benzothiazoles; Biopterins; Child; Dihydropteridine Reductase; Dopamine; Dopamine Agonists; Humans; Levodopa; Locomotion; Male; Phenylketonurias; Phosphorus-Oxygen Lyases; Pramipexole; Prolactin; Young Adult | 2012 |
Finasteride attenuates pathological gambling in patients with Parkinson disease.
Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games | 2012 |
Dopamine dysregulation syndrome including mania related to coadministration of droxidopa.
Topics: Aggression; Antiparkinson Agents; Behavior, Addictive; Benzothiazoles; Bipolar Disorder; Carbidopa; Droxidopa; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Pramipexole; Treatment Outcome | 2012 |
Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
Topics: Ankle; Antiparkinson Agents; Benserazide; Benzothiazoles; Drug Therapy, Combination; Edema; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline | 2012 |
Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Confidence Intervals; Disorders of Excessive Somnolence; Disruptive, Impulse Control, and Conduct Disorders; Dizziness; Dopamine Agonists; Drug Therapy, Combination; Female; Hallucinations; Humans; Indoles; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Time Factors | 2012 |
Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely.
Topics: Antiparkinson Agents; Benzothiazoles; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Reproducibility of Results; Severity of Illness Index; Telemedicine; Tremor | 2013 |
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate | 2012 |
A cup of coffee a day keeps dyskinesia away?
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Benzothiazoles; Caffeine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Pramipexole | 2013 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline | 2013 |
Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Levodopa; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Parkinson Disease; Pramipexole; Presynaptic Terminals; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes | 2013 |
Choreo-athetosis in LRRK2 R1441C mutation: expanding the clinical phenotype.
Topics: Antiparkinson Agents; Athetosis; Benzothiazoles; Chorea; Female; Gait Disorders, Neurologic; Humans; Hypokinesia; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Magnetic Resonance Imaging; Middle Aged; Mutation; Neurologic Examination; Phenotype; Positron-Emission Tomography; Pramipexole; Protein Serine-Threonine Kinases; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tremor | 2013 |
Therapeutic response to pramipexole in a patient with multiple system atrophy with predominant parkinsonism: positron emission tomography and pharmacokinetic assessments.
Topics: Antiparkinson Agents; Benzothiazoles; Brain; Comorbidity; Dose-Response Relationship, Drug; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Treatment Outcome | 2013 |
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocampus; Levodopa; Male; Motor Activity; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Substantia Nigra; Time Factors | 2014 |
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Aged; Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Sex Factors; Tetrahydronaphthalenes; Thiophenes | 2014 |
[Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
Topics: Aged; Benzothiazoles; Delayed-Action Preparations; Drug Substitution; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pramipexole; Selegiline | 2015 |
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation | 2015 |
Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apathy; Benzothiazoles; Cross-Sectional Studies; Dopamine Agonists; Educational Status; Female; Humans; Indoles; Levodopa; Male; Mental Disorders; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pramipexole; Prospective Studies; Psychotropic Drugs; Spain | 2015 |
Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzothiazoles; Cluster Analysis; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Levodopa; Male; Microarray Analysis; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2016 |
Variable frequency stimulation of subthalamic nucleus for freezing of gait in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agonists; Gait Disorders, Neurologic; Humans; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Pramipexole; Subthalamic Nucleus | 2015 |
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Brain; Chorea; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Spinocerebellar Ataxias; TATA-Box Binding Protein; Trinucleotide Repeats | 2016 |
A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole.
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Drug Combinations; Drug Therapy, Combination; Edema; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Treatment Outcome | 2016 |
Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; Dopamine; Female; Humans; Impulsive Behavior; Levodopa; Male; Parkinson Disease, Secondary; Pramipexole; Rats; Receptor, Metabotropic Glutamate 5 | 2017 |
Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; CD4-Positive T-Lymphocytes; Cytokines; Female; Humans; Immunophenotyping; Leukocytes, Mononuclear; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2018 |
Correspondence: The pathophysiology of pramipexole-associated dystonia in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dystonia; Humans; Levodopa; Parkinson Disease; Pramipexole | 2017 |
[Stealing as an Impulse Control Disorder Associated with Pramipexole - A Case Report from Forensic Psychiatric Practice].
Topics: Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Expert Testimony; Female; Humans; Levodopa; Mental Competency; Middle Aged; Parkinson Disease; Pramipexole; Risk Factors; Theft | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Dopamine modulates striatal response to reward and punishment in patients with Parkinson's disease: a pharmacological challenge fMRI study.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Dopamine; Dopamine Agonists; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Pramipexole; Punishment; Reward | 2018 |
[Severe leg edema associated with the use of dopaminergic drugs in Parkinson's disease. Report of one case].
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Edema; Humans; Leg; Levodopa; Male; Parkinson Disease; Pramipexole | 2017 |
Lesson of the month 2: An unusual adverse reaction associated with pramipexole.
Topics: Carbidopa; Dermatitis, Phototoxic; Dopamine Agonists; Drug Combinations; Drug Substitution; Humans; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Pramipexole | 2018 |
Novel contribution to the simultaneous monitoring of pramipexole dihydrochloride monohydrate and levodopa as co-administered drugs in human plasma utilizing UPLC-MS/MS.
Topics: Administration, Intravenous; Chromatography, High Pressure Liquid; Dopamine Agonists; Drug Stability; Humans; Levodopa; Pramipexole; Tandem Mass Spectrometry | 2018 |
Drug-induced gambling disorder: A not so rare but underreported condition.
Topics: Aged; Aged, 80 and over; Dopamine Agonists; Gambling; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2018 |
Evaluation of the effect of non-ergot dopamine agonists on left ventricular systolic function with speckle tracking echocardiography.
Topics: Aged; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Turkey; Ventricular Dysfunction, Left | 2018 |
Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Gambling; Humans; Italy; Levodopa; Male; Parkinson Disease; Pramipexole | 2020 |
The therapeutic role of repetitive transcranial magnetic stimulation (rTMS) in parkinsonian visual hallucinations: Electrophysiological correlates.
Topics: Aged, 80 and over; Antiparkinson Agents; Electroencephalography; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Pramipexole; Transcranial Magnetic Stimulation | 2019 |
Immunomodulatory effect and clinical outcome in Parkinson's disease patients on levodopa-pramipexole combo therapy: A two-year prospective study.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunologic Factors; Levodopa; Longitudinal Studies; Parkinson Disease; Pramipexole; Prospective Studies; Time Factors; Treatment Outcome | 2020 |
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome.
Topics: Adult; Antiparkinson Agents; Deamino Arginine Vasopressin; Demyelinating Diseases; Dystonia; Epistaxis; Hemostatics; Humans; Hyponatremia; Levodopa; Locked-In Syndrome; Male; Myelinolysis, Central Pontine; Osmotic Pressure; Parkinsonian Disorders; Postoperative Hemorrhage; Pramipexole; Pseudobulbar Palsy; Rhinoplasty; Tetrahydronaphthalenes; Thiophenes; Treatment Failure; Treatment Outcome; von Willebrand Disease, Type 1 | 2020 |
Dilemma in Parkinson's Treatment; Levodopa Monotherapy May be the Best Choice.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Depression; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Pramipexole; Psychotic Disorders; Quality of Life | 2020 |
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease.
Topics: Affect; Animals; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Ultrasonic Waves; Vocalization, Animal | 2021 |
Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Dopamine Agonists; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Regression Analysis; Retrospective Studies; Sleep; Tetrahydronaphthalenes; Thiophenes | 2021 |
Pramipexole treatment attenuates mechanical hypersensitivity in male rats experiencing chronic inflammatory pain.
Topics: Analgesics, Opioid; Animals; Chronic Pain; Dopamine; Hyperalgesia; Levodopa; Male; Pramipexole; Rats; Rats, Long-Evans | 2022 |
Restless legs syndrome in DNAJC12 deficiency.
Topics: Adult; Dopamine; Dopamine Agonists; Humans; Levodopa; Pramipexole; Restless Legs Syndrome | 2023 |
15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson's disease patient with Parkin gene mutation: a case report.
Topics: Adult; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Male; Mutation; Parkinson Disease; Pramipexole; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2023 |
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
Topics: alpha-Synuclein; Animals; Cognition; Dopamine; Dopaminergic Neurons; Hippocampus; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Rats | 2023 |